Business Context and Reporting Period
Sunshine Biopharma Inc. filed this Form 8-K on January 20, 2011, reporting events occurring on January 17, 2011. The company is a small business issuer incorporated in Colorado with principal executive offices in Montreal, Quebec, Canada.
Key Financial Metrics
This filing is a Current Report regarding a material definitive agreement and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes
The primary material change reported is the execution of a Research Agreement with The Research Foundation of the State University of New York (acting for Binghamton University). Key terms include:
- Objective: Advance lead compounds Adva-27a and Adva-32a through preclinical development, animal studies, and Phase I clinical trials for breast and prostate cancer.
- Duration: Three years from the effective date, with automatic one-year renewals until project completion.
- Exclusivity: The relationship is exclusive in the United States.
- Funding Mechanism: Work is contingent upon securing grants from Federal, State, local, or private sources as co-applicants. No definitive funding agreement was in place at the time of filing.
- Termination: The agreement terminates if funding is not obtained or is insufficient.
- Future Options: Binghamton University retains an option to continue development through Phase II and Phase III trials to FDA approval on terms to be mutually agreed.
Guidance, Outlook, and Risks
Management expressed confidence that the parties will secure necessary funding in the near future based on existing discussions. However, the filing explicitly states there can be no assurances that funding will be secured in an amount sufficient to conduct the project, or at all. The project's continuation is entirely dependent on the procurement of external grants.
Investor Verification Checklist
- Verify the status of grant applications submitted by Sunshine Biopharma and Binghamton University.
- Confirm whether definitive funding agreements have been executed since the filing date.
- Review the full text of the Research Agreement (Exhibit 10.4) for specific milestones and termination clauses.
- Assess the company's current cash runway given the lack of immediate funding for the project.